Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

November 13, 2007
Amgen, Who are they advocating for???
By a GLG Expert Contributor
Analysis of: Amgen Spends Big Protesting Curbs On Anemia Drugs (online.wsj.com)
Amgen is going public to protest Medicare restrictions on their Epo agents. They appear to be soliciting cancer patients, families and legislators to appeal the VERY FAIR decision.
November 12, 2007
Screening Cat Scans Reduce Lung Cancer Mortality???
By a GLG Expert Contributor
Analysis of: Long-term follow-up study of a population-based 1996–1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography (www.lungcancerjournal.info)
Early diagnosis and therapy of lung cancer can be expedited by screening CT's
November 12, 2007
More trouble for Amgen & J &J. FDA tightening control of Epo use
By a GLG Expert Contributor
Analysis of: Label for Anemia Drugs Likely Won't Help Sales (online.wsj.com)
The FDA is tightening up on guidelines for use of Epogen, Aranesp & Procrit in patients with anemia with recommendations to keep the Hemoglobin < 12 due to fear of increased cancer growth and cardiovascular problems. "A spokeswoman for J&J unit Ortho Biotech points to data indicating some...
November 8, 2007
Is there a Dr. in The House,ER,Soaps,Ben Casey, Dr. Kildare,Chicago Hope, etc or is it an illusion?
By a GLG Expert Contributor
Analysis of: At Real Hospitals, Less Trauma…and Drama (well.blogs.nytimes.com)
?? How realistic are todays Hospital/Doctor shows??
November 8, 2007
Bite (Micromet). Is it's bark worse than it's......
By a GLG Expert Contributor
Analysis of: Micromet's BiTE(R) Antibodies Reveal Unique Mode of Action (www.pipelinereview.com)
Interesting mechanism of action for this antibody that will activate T Cells (part of the bodies killer cell network) to kill the cancer. Rather cool!!
November 8, 2007
"High quality" care and communication with patients will be rewarded- When Pigs Fly....
By a GLG Expert Contributor
Analysis of: A Model for Health Care That Pays for Quality (www.nytimes.com)
Primary care doctors will receive financial incentives for communication as well as managing chronic conditions. E-mail and phone access will be rewarded.(?)
November 6, 2007
Asentar(TM) (DN-101,Novacea) Phase III Trial Terminated for Safety concerns??
By a GLG Expert Contributor
Analysis of: Novacea Halts ASCENT-2 Trial in Advanced Prostate Cancer (www.therapeuticsdaily.com)
Apparently an increased # of deaths in the Asentar/Taxotere arm BUT I don't know what the control arm contained. It is described as "the current standard of care."
November 5, 2007
PBI-1402 How Exciting for Anephric Rats.....
By a GLG Expert Contributor
Analysis of: Prometic Reports Positive Pre-Clinical Data for PBI-1402 in Anemia Related to Renal Failure (www.marketwire.com)
This product increased hemoglobin levels in anephric (kidneys removed) rats. This is the initial pre-clinical study for use in human renal failure associated anemia.
November 5, 2007
MP470 In Vitro or In Vivo, no human trials yet......
By a GLG Expert Contributor
Analysis of: Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme (www.bio-medicine.org)
SuperGen Inc. (Nasdaq: SUPG) has a multitargeted tyrosine kinase inhibitor (TKI) active against Glioblastoma Multiforme (GBM)  BUT NOT TESTED IN HUMANS.
November 1, 2007
"Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture" Yea!! It appears to!!!
By a GLG Expert Contributor
Analysis of: Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture (content.nejm.org)
That giving Zometa Novartis) reduces incidence of repeat fractures after hip fx repair and improves survival?

Previous Page : 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Next241 to 250 of 457

Analytics


Generated at 2009-01-07T19:00:58.307